Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Address

3150 Almaden Expressway

Suite 250

Website

https://www.anixa.com

Classification

Sector

Healthcare

Industry Group

Biotechnology

Industry

Biotechnology

Key Executives

Dr. Amit Kumar,PhD

CEO/Chairman of the Board/Director

Mr. Lewis H. Titterton, Jr

Director

Dr. Arnold Baskies, M.D.

Director

Mr. Michael J. Catelani

CFO/Chief Accounting Officer/COO/President

Ms. Emily Gottschalk

Director

Ownership

Institution Holdings

Vanguard Group Inc

1,392,906 (4.392%)

Vanguard Investments Australia Ltd

927,841 (2.926%)

UBS Group AG

580,578 (1.831%)

Mission Wealth Management, LLC

501,168 (1.580%)

Laird Norton Tyee Trust Co

368,835 (1.163%)

Geode Capital Management, LLC

312,472 (0.985%)

Fidelity Management & Research Company LLC

287,431 (0.906%)

Long Focus Capital Management, LLC

165,701 (0.523%)

BlackRock Inc

156,797 (0.494%)

State Street Corporation

108,500 (0.342%)

Individual Holdings

Mr. Lewis H. Titterton, Jr

823,028 (2.649%)

Dr. Amit Kumar,PhD

461,925 (1.489%)

Dr. Arnold Baskies, M.D.

100,000 (0.334%)

Ms. Emily Gottschalk

45,665 (0.153%)

Mr. Michael J. Catelani

27,772 (0.089%)

Funds Holdings

BlackRock Extended Equity Market

72,974 (0.230%)

Fidelity Series Total Market Index Fund

41,099 (0.130%)

NT Ext Equity Mkt Idx Fd - DC - NL

18,696 (0.059%)

Extended Equity Market Fund M

9,023 (0.028%)

SSgA U.S. Total Market Index Fund

2,106 (0.007%)

BNYM Mellon SL Market Completion Fund

1,714 (0.005%)

NT Ext Equity Mkt Indx Fd DC Lending

753 (0.002%)

Details

Overview

Company Info

Key Ratios

Income

Balance Sheet

Cash Flow

Bubble

Make Smart Investment Choices